Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC01009
- Development stage
- Phase 2
- Lead developer
- Zhejiang Shengchuang Precision Medical Technology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
SC01009 is an allogeneic cell therapy product composed of menstrual blood-derived mesenchymal stem cells (Men-MSCs). Developed by Zhejiang Shengchuang Precision Medical Technology, SC01009 leverages the multipotent properties of MSCs, which are characterized by their ability to self-renew, differentiate into multiple lineages, and exhibit low immunogenicity. The therapeutic mechanism involves the cells homing to damaged tissue areas, where they exert paracrine effects to promote epithelial tissue repair, suppress inflammation, and inhibit the abnormal proliferation of fibroblasts. The drug is currently being investigated for the treatment of severe respiratory conditions, including idiopathic pulmonary fibrosis (IPF) and severe viral pneumonia caused by pathogens such as influenza or respiratory syncytial virus.
- Other names
- Men-MSCsMenstrual blood-derived Mesenchymal Stem CellsMenstrual blood-derived Mesenchymal Stem Cells injection
Beyond the preview
Go deeper on SC01009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC01009.